Protecting the Brain After Stroke

Episode Summary

Executive Summary: Greg Archambeau of Revelicio describes RNS-60, an oxygenated saline infusion designed to protect mitochondria and reduce reperfusion injury in ischemic stroke. He argues Phase 2 data showed meaningful improvements in brain volume loss, 90-day function, and hospital stay, and says the therapy could improve stroke recovery and hospital economics while extending to other neurodegenerative diseases.

Main Topics: Mitochondrial dysfunction in stroke (Priority: 5/5): Archambeau explains that neurons are highly energy-dependent, and ischemic stroke deprives mitochondria of oxygen and energy, triggering cell death, inflammation, and tissue loss. Reperfusion injury and thrombectomy (Priority: 5/5): The discussion frames mechanical thrombectomy as the current gold standard, but notes that restoring blood flow can generate reactive oxygen species and worsen injury. What RNS-60 is and how it works (Priority: 5/5): RNS-60 is described as oxygenated saline with effects beyond oxygen delivery, reportedly stimulating mitochondrial function, preserving mitochondrial structure, and activating pro-survival signaling. Phase 2 proof-of-concept results (Priority: 5/5): Archambeau highlights biomarker and clinical improvements in large-vessel-occlusion stroke patients, including better 90-day outcomes and reduced infarct growth. Hospital stay and health economics (Priority: 4/5): He emphasizes shorter hospitalizations, more discharge to home, and the potential for improved stroke-center capacity and payer economics. Phase 3 design and regulatory path (Priority: 4/5): The planned Phase 3 trial mirrors Phase 2 but focuses on patients within 12 hours of stroke onset and uses modified Rankin Scale as the primary endpoint. Platform potential beyond stroke (Priority: 3/5): Revelicio sees RNS-60 as a broader neuroprotective platform for ALS, Alzheimer’s disease, and traumatic brain injury because of its mitochondrial-supporting biology.

Key Arguments: Mitochondria are central to brain energy use, so ischemia quickly creates neuronal stress and drives stroke damage. Mechanical thrombectomy restores blood flow but can also cause reperfusion injury through oxidative stress and inflammatory signaling. RNS-60 is more than oxygenated saline; it appears to activate pro-survival pathways and preserve mitochondrial structure under stress. The preclinical and Phase 2 findings are consistent across labs and models, suggesting the effect is real rather than placebo. A biomarker approach using MRI-measured infarct volume growth at 48 hours correlated strongly with 90-day function. The therapy may change hospital economics by reducing length of stay and increasing discharge to home. Stroke is an especially difficult indication because many prior neuroprotective therapies have failed, making reproducibility in Phase 3 essential. The broad, multi-cell-type mechanism may fit stroke biology better than narrowly targeted drugs because stroke injury evolves over 24-48 hours.

Data Points: Poor outcomes after clot removal: more than half of patients - Current gold-standard thrombectomy still leaves many ischemic stroke patients with poor 90-day outcomes. Best standard-of-care functional outcome in large-vessel-occlusion stroke: 40-45% good outcomes at 90 days - Baseline comparator cited by Archambeau for thrombectomy-treated patients. Phase 2 sample size: about 25 individuals per arm - Small proof-of-concept stroke study. Reduction in brain volume loss: 50% reduction - Preclinical rodent and primate stroke models. RNS-60 outcome in Phase 2: 63% good outcomes at 90 days - High-dose RNS-60 group in proof-of-concept study. Earlier-treatment subgroup outcome: 72% good outcomes at 90 days - Patients treated within 12 hours in the study subgroup analysis. Placebo outcome in Phase 2: 46% good outcomes at 90 days - Matches expected real-world stroke outcome range. Hospital length of stay with RNS-60: 6 days - Average discharge timing for treated patients. Hospital length of stay with placebo: 11 days - Average discharge timing for placebo patients. Reduction in hospital stay: 5 days - Difference between RNS-60 and placebo groups. Increase in discharge home: about 40% more patients - More treated patients went home rather than to rehabilitation facilities. RNS-60 oxygen concentration: 60 milligrams per liter - Saline saturated with oxygen as described by the company. Publication timeline: a few weeks away - Upcoming Muscle and Nerve paper on ALS mouse-model mitochondrial structure. Phase 3 enrollment window: within 12 hours - Eligibility tightened from 24 hours after Phase 2 showed stronger results.

Pivotal Quotes: "You have the reestablishment of blood flow is essential. But in doing that, there's some damaging products that can go downstream, like O2 radicals that have been created by that compromised mitochondria." — Greg Archambeau: Explaining reperfusion injury after thrombectomy "We saw a great correlation between infarct volume growth during that 48 hours post-the clot being removed and 90-day function." — Greg Archambeau: Describing the Phase 2 biomarker strategy "RNS-60 represents somewhat of a platform." — Greg Archambeau: On the therapy's potential beyond stroke

Implications: If Phase 3 confirms Phase 2, RNS-60 could become an add-on to thrombectomy that improves recovery, shortens stays, and eases stroke-center burden, while opening a broader pipeline in neurodegeneration.